Literature DB >> 29155789

Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System.

Anjali Nandal1, Barbara Mallon2, Bhanu P Telugu3.   

Abstract

Embryonic and induced pluripotent stem cells can self-renew and differentiate into multiple cell types of the body. The pluripotent cells are thus coveted for research in regenerative medicine and are currently in clinical trials for eye diseases, diabetes, heart diseases, and other disorders. The potential to differentiate into specialized cell types coupled with the recent advances in genome editing technologies including the CRISPR/Cas system have provided additional opportunities for tailoring the genome of iPSC for varied applications including disease modeling, gene therapy, and biasing pathways of differentiation, to name a few. Among the available editing technologies, the CRISPR/Cas9 from Streptococcus pyogenes has emerged as a tool of choice for site-specific editing of the eukaryotic genome. The CRISPRs are easily accessible, inexpensive, and highly efficient in engineering targeted edits. The system requires a Cas9 nuclease and a guide sequence (20-mer) specific to the genomic target abutting a 3-nucleotide "NGG" protospacer-adjacent-motif (PAM) for targeting Cas9 to the desired genomic locus, alongside a universal Cas9 binding tracer RNA (together called single guide RNA or sgRNA). Here we present a step-by-step protocol for efficient generation of feeder-independent and footprint-free iPSC and describe methodologies for genome editing of iPSC using the Cas9 ribonucleoprotein (RNP) complexes. The genome editing protocol is effective and can be easily multiplexed by pre-complexing sgRNAs for more than one target with the Cas9 protein and simultaneously delivering into the cells. Finally, we describe a simplified approach for identification and characterization of iPSCs with desired edits. Taken together, the outlined strategies are expected to streamline generation and editing of iPSC for manifold applications.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29155789      PMCID: PMC5755356          DOI: 10.3791/56260

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  17 in total

1.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.

Authors:  Alexis C Komor; Ahmed H Badran; David R Liu
Journal:  Cell       Date:  2017-04-20       Impact factor: 41.582

2.  Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells.

Authors:  Alireza Rezania; Jennifer E Bruin; Payal Arora; Allison Rubin; Irina Batushansky; Ali Asadi; Shannon O'Dwyer; Nina Quiskamp; Majid Mojibian; Tobias Albrecht; Yu Hsuan Carol Yang; James D Johnson; Timothy J Kieffer
Journal:  Nat Biotechnol       Date:  2014-09-11       Impact factor: 54.908

Review 3.  Induced Pluripotent Stem Cells Meet Genome Editing.

Authors:  Dirk Hockemeyer; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2016-05-05       Impact factor: 24.633

Review 4.  Induced pluripotent stem cell technology: a decade of progress.

Authors:  Yanhong Shi; Haruhisa Inoue; Joseph C Wu; Shinya Yamanaka
Journal:  Nat Rev Drug Discov       Date:  2016-12-16       Impact factor: 84.694

5.  Enhanced CRISPR/Cas9-mediated precise genome editing by improved design and delivery of gRNA, Cas9 nuclease, and donor DNA.

Authors:  Xiquan Liang; Jason Potter; Shantanu Kumar; Namritha Ravinder; Jonathan D Chesnut
Journal:  J Biotechnol       Date:  2016-11-11       Impact factor: 3.307

6.  Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.

Authors:  Kazutoshi Takahashi; Shinya Yamanaka
Journal:  Cell       Date:  2006-08-10       Impact factor: 41.582

7.  Induced pluripotent stem cell lines derived from human somatic cells.

Authors:  Junying Yu; Maxim A Vodyanik; Kim Smuga-Otto; Jessica Antosiewicz-Bourget; Jennifer L Frane; Shulan Tian; Jeff Nie; Gudrun A Jonsdottir; Victor Ruotti; Ron Stewart; Igor I Slukvin; James A Thomson
Journal:  Science       Date:  2007-11-20       Impact factor: 47.728

Review 8.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes.

Authors:  Alexis C Komor; Ahmed H Badran; David R Liu
Journal:  Cell       Date:  2016-11-17       Impact factor: 41.582

9.  Generation of human-induced pluripotent stem cells by a nonintegrating RNA Sendai virus vector in feeder-free or xeno-free conditions.

Authors:  Chad C Macarthur; Andrew Fontes; Namritha Ravinder; David Kuninger; Jasmeet Kaur; Matthew Bailey; Antje Taliana; Mohan C Vemuri; Pauline T Lieu
Journal:  Stem Cells Int       Date:  2012-03-22       Impact factor: 5.443

10.  Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome.

Authors:  Noemi Fusaki; Hiroshi Ban; Akiyo Nishiyama; Koichi Saeki; Mamoru Hasegawa
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2009       Impact factor: 3.493

View more
  3 in total

Review 1.  Current approaches in regenerative medicine for the treatment of diabetes: introducing CRISPR/CAS9 technology and the case for non-embryonic stem cell therapy.

Authors:  Lauren Coombe; Aamir Kadri; Jessica Ferrer Martinez; Vivas Tatachar; Gary Ian Gallicano
Journal:  Am J Stem Cells       Date:  2018-12-01

2.  Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms.

Authors:  Behnom Farboud; Erin Jarvis; Theodore L Roth; Jiyung Shin; Jacob E Corn; Alexander Marson; Barbara J Meyer; Nipam H Patel; Megan L Hochstrasser
Journal:  J Vis Exp       Date:  2018-05-25       Impact factor: 1.355

Review 3.  Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research.

Authors:  Ming Hu; Ines Cherkaoui; Shivani Misra; Guy A Rutter
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-08       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.